CD-001

DRUG2 trials

Sponsors

CD (Suzhou) Biopharma Co., Ltd., West China Hospital

Conditions

Advanced Head and Neck CarcinomaAdvanced Solid TumorsHead &Amp; Neck CancerHead and Neck CancerMalignant Neoplasm

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors

RecruitingNCT06801470

CD (Suzhou) Biopharma Co., Ltd.Advanced Solid Tumors

Start: 2025-01-08End: 2028-06-30Target: 137Updated: 2025-02-07

Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers

Not yet recruitingNCT07072325

West China HospitalAdvanced Head and Neck Carcinoma, Head &Amp; Neck Cancer, Head and Neck Cancer +1

Start: 2025-08-10End: 2028-08-31Target: 9Updated: 2025-08-03